This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Regeneron can't get injunction against Amgen over eye medication, US appeals court says

By Nick Robertson ( March 17, 2025, 13:45 GMT | Insight) -- The US Court of Appeals for the Federal Circuit affirmed Friday that Regeneron is not likely to succeed on the merits in patent litigation against Amgen over its eye medication Eylea, denying Regeneron’s motion for a preliminary injunction. The court affirmed that the Amgen biosimilar formulation’s exclusion of the “buffer” substance in the drug differentiates it from Regeneron’s original and other biosimilars.Amgen will not be hit with a preliminary injunction over its biosimilar version of Regeneron’s Eylea eye medication, the US Court of Appeals for the Federal Circuit affirmed on Friday in a precedential decision. Regeneron is not likely to succeed on the merits in its infringement claims, the court held, as Amgen’s biosimilar drug is differentiated from Regeneron’s original....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections